Just one shot of the Mpox vaccine reduces the risk of infection by 86% compared to those who are unvaccinated, according to a new study published recently in Nature Medicine.
The real-world study – the first to be published in a peer-reviewed journal since the outbreak began last spring – tested the effectiveness of a single dose of the live attenuated vaccine, produced by Bavarian Nordic (MVA-BN) in preventing cases of symptomatic infection.
The observational study, conducted by Israel’s largest health fund, Clalit Health Services, followed 2,054 men, who were eligible for the vaccine, 50% of whom were vaccinated during the study recruitment period and completed at least 90 days of follow-up. During the study period, only 5 members of the vaccinated group came down with symptomatic Mpox infection, as compared to 16 cases in the unvaccinated individuals, respectively.
Read the full story at Health Policy Watch.
Source : Health Policy Watch
Related HIV and Co-Infections News
-
NDTV: Mpox can infect and replicate in the brain, NIH researchers say in fatal HIV case
-
[Press release] University of Barcelona: People with HIV did not show more severe clinical symptoms during the 2022 mpox outbreak in Spain
-
[CROI 2026] Healio: Tecovirimat lacks potency against mpox, more studies show
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.